RxDoctor Payments Data

Baher Basta, MD

Nephrology · Chesapeake, VANPI 1538130257

Payments from drug & device makers

$557in general payments, 2019–2025

Across 26 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$92
  • Otsuka America Pharmaceutical, Inc.$78
  • AstraZeneca$77
  • Mallinckrodt Enterprises LLC$62
  • Calliditas Therapeutics US Inc.$51
  • Mallinckrodt Hospital Products Inc.$50
  • plus $147 from 7 others

What the payments were for

  • Food & beverage$48587%
  • Education$7213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$557 in reported general payments places this provider in the 35th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$78,524
Medicare patients
190
Services billed
778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin15$39,027
OzempicSemaglutide12$11,720
Amlodipine Besylate14$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$29$11,72012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 298 nephrology providers in Virginia.

Other nephrology in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →